Magnetic Resonance Imaging (MRI) to Evaluate Activity of Multiple Sclerosis (MS)

Launched by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) · Nov 3, 1999

Keywords

ClinConnect Summary

This clinical trial is studying the effects of Multiple Sclerosis (MS) through Magnetic Resonance Imaging (MRI) and other tests. It aims to understand how MS progresses in patients who are untreated as well as those who are receiving approved treatments. Researchers will take regular MRI scans to look for signs of disease activity, such as new lesions in the brain and overall brain health, and compare these findings with the patients' immune system responses. This will help them learn more about how the disease works and how it responds to different therapies.

To participate in this study, individuals must be at least 18 years old and either have a confirmed diagnosis of MS or show symptoms that suggest MS. Healthy volunteers are also welcomed to help establish normal benchmarks for the study. Participants can expect to undergo a series of MRI scans and other assessments over time, which will help researchers gather important data. It's important to note that anyone with a condition that prevents them from having an MRI won't be able to join the study. This research could lead to a better understanding of MS and improve ways to treat it in the future.

Gender

ALL

Eligibility criteria

• * INCLUSION CRITERIA:
• In order to be eligible to participate in this study, an individual must meet all of the following criteria:
• 1. One of the following:
• • 1. Affected participant with either a diagnosis of MS based on currently accepted diagnostic criteria, or imaging or clinical abnormalities associated with MS.
• • 2. Healthy volunteer.
• • 2. Age \>=18
• • 3. Able to give informed consent.
• EXCLUSION CRITERIA:
• An individual who meets any of the following criteria will be excluded from participation in this study:
• • 1. Contraindication to MRI at the time of initial enrollment (with the exception of pregnancy).
• • 2. Unwilling to allow coded samples to be processed offsite or unwilling to have coded samples used in other studies.